Autoimmune hepatitis
Conditions
Interventions
AIH group:None
DILI group:None
Sponsors
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Clinical diagnostic criteria: For AIH, diagnosis conforms to the Guidelines for the Diagnosis and Management of Autoimmune Hepatitis (2021 Edition) and is pathologically confirmed by liver biopsy. For DILI, diagnosis follows the Guidelines for the Diagnosis and Treatment of Drug-Induced Liver Injury (2023 Edition) with a RUCAM score >=6, and alternative liver diseases are excluded via liver biopsy; 2.No prior immunosuppressant administration before liver biopsy; if brief immunosuppressive therapy was given, the treatment duration is less than 1 week to avoid interference with pathological findings and all dimensional laboratory measurements. 3.Complete datasets are available, including clinical documentation, serological test results, hepatic MRI images, liver biopsy specimens, and serum samples collected concurrently with biopsy for subsequent glycomic analysis. 4. Age >=18 years and <=80 years, any gender.
Exclusion criteria
Exclusion criteria: 1.Coexistence of other liver diseases, including viral hepatitis, non-alcoholic fatty liver disease, alcoholic liver disease, hepatocellular carcinoma, etc. 2.Concurrent other autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, primary biliary cholangitis) that may interfere with the detection of autoantibodies and immune parameters. 3.Inadequate liver biopsy specimens (fewer than 10 portal tracts) or unqualified pathological sections unavailable for pathological evaluation. 4.Hepatic MRI images with severe artifacts or incomplete scanning parameters, precluding subsequent radiomic analysis. 5.Insufficient or improperly preserved serum samples that cannot fulfill serological and glycomic testing. 6.Accompanied by severe dysfunction of vital organs (heart, kidney, lung, brain), malignant tumors or coagulation disorders which may confound study outcomes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diagnostic performance;Lab blood test markers; | — |
Countries
China
Contacts
Public ContactGui Honglian
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
Outcome results
None listed